^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2102
i
Other names: TQB2102
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
2ms
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (clinicaltrials.gov)
P2, N=104, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
TQB2102
4ms
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (clinicaltrials.gov)
P2, N=104, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial
|
TQB2102
5ms
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=150, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
TQB2102
6ms
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=150, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
TQB2102
1year
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers (clinicaltrials.gov)
P1, N=71, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
TQB2102
Share via
